...
首页> 外文期刊>BMC Medical Genomics >A method to reduce ancestry related germline false positives in tumor only somatic variant calling
【24h】

A method to reduce ancestry related germline false positives in tumor only somatic variant calling

机译:减少仅肿瘤体细胞变异的祖先相关种系假阳性的方法

获取原文
           

摘要

Significant clinical and research applications are driving large scale adoption of individualized tumor sequencing in cancer in order to identify tumors-specific mutations. When a matched germline sample is available, somatic mutations may be identified using comparative callers. However, matched germline samples are frequently not available such as with archival tissues, which makes it difficult to distinguish somatic from germline variants. While population databases may be used to filter out known germline variants, recent studies have shown private germline variants result in an inflated false positive rate in unmatched tumor samples, and the number germline false positives in an individual may be related to ancestry. First, we examined the relationship between the germline false positives and ancestry. Then we developed and implemented a tumor only caller (LumosVar) that leverages differences in allelic frequency between somatic and germline variants in impure tumors. We used simulated data to systematically examine how copy number alterations, tumor purity, and sequencing depth should affect the sensitivity of our caller. Finally, we evaluated the caller on real data. We find the germline false-positive rate is significantly higher for individuals of non-European Ancestry largely due to the limited diversity in public polymorphism databases and due to population-specific characteristics such as admixture or recent expansions. Our Bayesian tumor only caller (LumosVar) is able to greatly reduce false positives from private germline variants, and our sensitivity is similar to predictions based on simulated data. Taken together, our results suggest that studies of individuals of non-European ancestry would most benefit from our approach. However, high sensitivity requires sufficiently impure tumors and adequate sequencing depth. Even in impure tumors, there are copy number alterations that result in germline and somatic variants having similar allele frequencies, limiting the sensitivity of the approach. We believe our approach could greatly improve the analysis of archival samples in a research setting where the normal is not available.
机译:重要的临床和研究应用正在推动癌症中个体化肿瘤测序的大规模采用,以鉴定肿瘤特异性突变。当有匹配的种系样品可用时,可以使用比较调用子鉴定体细胞突变。但是,匹配的种系样品通常无法获得,例如档案组织,因此很难区分体细胞和种系变体。尽管可以使用种群数据库过滤掉已知的种系变异,但最近的研究表明,私人种系变异导致不匹配的肿瘤样本中的假阳性率升高,并且个体中种系假阳性的数量可能与血统有关。首先,我们研究了种系假阳性与血统之间的关系。然后,我们开发并实现了一个仅肿瘤的调用程序(LumosVar),该调用程序利用了不纯肿瘤中体细胞和种系变体之间等位基因频率的差异。我们使用模拟数据系统地检查了拷贝数变化,肿瘤纯度和测序深度应如何影响呼叫者的敏感性。最后,我们根据真实数据评估了调用方。我们发现非欧洲祖先个体的种系假阳性率显着较高,这主要是由于公共多态性数据库的多样性有限以及特定人群的特征(例如混合或最近的扩张)所致。我们的仅贝叶斯肿瘤调用者(LumosVar)能够极大地减少私人种系变异的假阳性,并且我们的敏感性类似于基于模拟数据的预测。综上所述,我们的结果表明,对非欧洲血统的个体的研究将最受益于我们的方法。然而,高灵敏度需要足够不纯的肿瘤和足够的测序深度。即使在不纯净的肿瘤中,也存在拷贝数变化,导致种系和体细胞变异体具有相似的等位基因频率,从而限制了方法的敏感性。我们认为,在无法获得正常值的研究环境中,我们的方法可以极大地改善档案样本的分析。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号